Enos

Bazefield and W3 Energy start cooperation

Retrieved on: 
Wednesday, March 8, 2023
BayWa, Invenergy, EDF Renewables, Enos, OEM, Artificial intelligence of things, Farm, Solar energy, Wind, SSE Renewables, Nordic, Renewable energy

UMEÅ, Sweden, March 8, 2023 /PRNewswire/ -- W3 Energy has signed a five-year cooperation agreement with Bazefield AS and thereby implements the EnOS Bazefield operating system in the business.

Key Points: 
  • UMEÅ, Sweden, March 8, 2023 /PRNewswire/ -- W3 Energy has signed a five-year cooperation agreement with Bazefield AS and thereby implements the EnOS Bazefield operating system in the business.
  • Swedish W3 Energy is one of the Nordics' leading players in the operation, management and optimization of wind farms.
  • This is exactly what Bazefield gives W3 Energy, and thus also their customers", she says.
  • The portfolio of 1860 MW means that approximately 18 % of the renewable energy produced in Sweden is managed by W3 Energy.

Titan Medical Granted Patent Covering User Experience, Further Enhancing its Intellectual Property in Robotic Assisted Surgery

Retrieved on: 
Tuesday, December 13, 2022
Movement, Surgeon, TMD, Motion, Anatomy, Sale, Hospital, ZEUS robotic surgical system, RAS, News, Patent, Infection, GUI, Enos, TSX, Growth, Patient, 3D printing, Titan

11,504,191, titled “Graphical User Interface for a Robotic Surgical System.” The patent, directed at enhancing the surgeon user experience, generally covers a graphical user interface (GUI) overlay of a surgical workspace to track instrument movement.

Key Points: 
  • 11,504,191, titled “Graphical User Interface for a Robotic Surgical System.” The patent, directed at enhancing the surgeon user experience, generally covers a graphical user interface (GUI) overlay of a surgical workspace to track instrument movement.
  • “The granting of this patent is a result of our strategic plan to independently build and protect a robust patent portfolio in robotic assisted surgery, including around the Enos™ robotic single access surgical system.
  • Today’s news validates our commitment to the continuum of innovation in robotic assisted surgery,” stated Cary Vance, President, and CEO of Titan.
  • Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company headquartered in Toronto, Ontario with operations in Chapel Hill, North Carolina, is focused on enhancing robotic assisted surgery (RAS) using innovative technology through a single access point.

Titan Medical Suspends Special Meeting of Shareholders in Conjunction with Initiation of Strategic Review Process

Retrieved on: 
Wednesday, December 7, 2022
Surgeon, TMD, Motion, FDA, Sale, IDE, Hospital, RAS, News, Infection, Enos, TSX, Growth, Patient, Medical device, Risk management, Titan

No future meeting dates have been scheduled and no decision on any specific business item for any future meeting of shareholders has been made at this time.

Key Points: 
  • No future meeting dates have been scheduled and no decision on any specific business item for any future meeting of shareholders has been made at this time.
  • Cary G. Vance, Titan’s President and CEO, commented, “After consultation with our financial and legal advisors, we determined it was in the best interest of the company and its shareholders to suspend the special meeting.
  • With the suspension of the special meeting of shareholders previously scheduled for January 12, 2023, the company will not at this time be relying on a share consolidation to regain compliance with the Nasdaq Rule 5550(a)(2).
  • Enos™ is a trademark of Titan Medical Inc.
    For more information, visit www.titanmedicalinc.com and follow @TitanMedical on Twitter and LinkedIn.

Titan Medical Implements Cost-Cutting Measures to Support Strategic Review Process

Retrieved on: 
Tuesday, December 6, 2022
Surgeon, TMD, Motion, Food, FDA, Sale, IDE, Hospital, RAS, News, Regulation of tobacco by the U.S. Food and Drug Administration, SEDAR, Infection, Enos, TSX, Growth, Patient, File, EDGAR, Pharmaceutical industry, 3D printing, Risk management, Titan

As part of this plan, the company’s U.S. subsidiary will be temporarily furloughing approximately 40 employees at its Chapel Hill, North Carolina facility effective immediately.

Key Points: 
  • As part of this plan, the company’s U.S. subsidiary will be temporarily furloughing approximately 40 employees at its Chapel Hill, North Carolina facility effective immediately.
  • Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company headquartered in Toronto, Ontario and with operations in Chapel Hill, North Carolina, is focused on enhancing robotic assisted surgery using innovative technology through a single access point.
  • On November 30, 2022, the company announced the commencement of a strategic review process that will consider a full range of strategic alternatives including corporate sale, merger or other business combination, a sale of all or a portion of the company’s assets, strategic investment or other significant transaction.
  • Enos™ is a trademark of Titan Medical Inc.

Titan Medical Announces Commencement of Strategic Review Process

Retrieved on: 
Wednesday, November 30, 2022
Growth, TMD, TSX, Hospital, RAS, Patient, Enos, Our Boarding House, News, Sale, Surgeon, Motion, Infection, Risk management, Titan

As part of the process, the Board will consider a full range of strategic alternatives including corporate sale, merger or other business combination, a sale of all or a portion of the companys assets, strategic investment or other significant transaction.

Key Points: 
  • As part of the process, the Board will consider a full range of strategic alternatives including corporate sale, merger or other business combination, a sale of all or a portion of the companys assets, strategic investment or other significant transaction.
  • As part of the strategic review process, the Company has engaged Raymond James as financial advisor to advise the Company in connection with this broad and comprehensive review and analysis of strategic alternatives.
  • We believe it is prudent to undertake a review of our strategic options to determine the best path forward to realize the value of our innovations in single-access robotic-assisted technologies to maximize shareholder value.
  • Enos is a trademark of Titan Medical Inc.
    For more information, visit www.titanmedicalinc.com and follow @TitanMedical on Twitter and LinkedIn.

Titan Medical Announces American Association of Gynecologic Laparoscopy Global Congress Participation

Retrieved on: 
Thursday, November 17, 2022
Aurora, Growth, TMD, TSX, Hospital, Physician, RAS, AAGL, Patient, Education, Enos, News, Surgeon, Innovation, Congress, Motion, Infection, Pharmaceutical industry, Dentistry, Titan, MIGS

TORONTO, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced its attendance at the American Association of Gynecologic Laparoscopy (AAGL) 51st Global Congress on minimally invasive gynecologic surgery (MIGS) being held December 1-4, 2022 in Aurora, Colorado.

Key Points: 
  • TORONTO, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced its attendance at the American Association of Gynecologic Laparoscopy (AAGL) 51st Global Congress on minimally invasive gynecologic surgery (MIGS) being held December 1-4, 2022 in Aurora, Colorado.
  • Participation at the American Association of Gynecologic Laparoscopy Global Congress aligns with Titans mission of improving outcomes for patients, hospitals and surgeons in our initial pursuit of gynaecological surgical indications.
  • AAGL is the largest medical society focused on gynecologic surgery, with an international membership of over 7,100 physicians and healthcare providers committed to advancing MIGS.
  • AAGLs Annual Global Congress is the premier scientific program that provides the worlds finest gynecologic surgeons with the latest education and best practices in MIGS.

Titan Medical Reports Financial Results for the Third Quarter 2022, and Announces Special Shareholder Meeting

Retrieved on: 
Thursday, November 10, 2022
Vance, GLOBE, Forward-looking statement, Marketing, TMD, Food, Research and development agreement, Webcast, RAS, Intention, Development, Classification, IDE, Investor relations, Regulation of tobacco by the U.S. Food and Drug Administration, R, Enos, News, Compliance, Time, Software, Company, Conference, Engineering, De novo, Medtronic, Surgeon, TSX, Growth, CEO, Motion, FDA, Trial of the century, Medical device, Risk management, Nasdaq, Titan, G&A

Titan is completing the final steps prior to the anticipated delivery of the first Enos system to its Chapel Hill facility before year-end 2022.

Key Points: 
  • Titan is completing the final steps prior to the anticipated delivery of the first Enos system to its Chapel Hill facility before year-end 2022.
  • Following submission, we expect to finalize our clinical trial design and continue to plan our commercialization strategy for the U.S. market.
  • Vance added, After careful consideration, the company has also decided to propose a consolidation of common shares to its shareholders.
  • ET today (November 10, 2022) to discuss the companys financial results for the three months ended September 30, 2022, and recent business highlights.

Titan Medical to Issue Third Quarter 2022 Financial Results on November 10, 2022

Retrieved on: 
Wednesday, November 2, 2022
Surgeon, Growth, News, GLOBE, Intention, Nasdaq, RAS, TSX, VP, TMD, Enos, Forward-looking statement, Motion, Titan

TORONTO, ON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced that the company plans to issue its third quarter 2022 financial results prior to market opening on Thursday, November 10, 2022.

Key Points: 
  • TORONTO, ON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced that the company plans to issue its third quarter 2022 financial results prior to market opening on Thursday, November 10, 2022.
  • ET to discuss financial results and business developments in the period.
  • Speakers will include Cary Vance, President and Chief Executive Officer, Stephen Lemieux, Chief Financial Officer and Kristen Galfetti, VP Investor Relations.
  • A link to the live audio webcast will be made available on the "Investor Relations" section of the companys website, www.titanmedicalinc.com .

Envision and Toyota Tsusho China Form Strategic Partnership for Net Zero Transition

Retrieved on: 
Thursday, October 20, 2022
Carbon, Quality of life, IIOT, City, Life, GHG, Electricity, Enos, Toyota Tsusho, Information economy, Shadow library, Partnership, Technology, Rights, Industry, Acts Retirement-Life Communities, United Kingdom, Envision, Solution, Compliance, Motor vehicle, Renewable energy

SHANGHAI, Oct. 20, 2022 /PRNewswire/ -- Envision, the global green tech partner for net zero, andToyota Tsusho (China) Co., Ltd. ("Toyota Tsusho China"), one of the leading Japanese General Trading Houses in Toyota Motor Group, today announced a strategic partnership in China to support the company and its clients' net zero transition.

Key Points: 
  • SHANGHAI, Oct. 20, 2022 /PRNewswire/ -- Envision, the global green tech partner for net zero, andToyota Tsusho (China) Co., Ltd. ("Toyota Tsusho China"), one of the leading Japanese General Trading Houses in Toyota Motor Group, today announced a strategic partnership in China to support the company and its clients' net zero transition.
  • The strategic partnership will also include cooperation on serving net zero solutions jointly to different clients to help them achieve their carbon emission reduction goals.
  • The signing of the strategic partnership took place in Shanghai between Mr Tatsuya Watanuki, Toyota Tsusho East Asia CEO, and Alex Sun, Vice President, Carbon Management, Envision Digital.
  • Alex Sun, Vice President, Carbon Management at Envision Digital, said "We are honoured to be selected by Toyota Tsusho China as a strategic partner for its net zero journey.

Titan Medical Announces Appointment of Eric Heinz as Vice President, Market and Corporate Development

Retrieved on: 
Monday, September 26, 2022
Master of Engineering Management, Engineering, TSX, TMD, IMRIS, Intention, Growth, News, Champaign–Urbana metropolitan area, Industry, University, RAS, Forward-looking statement, Biological engineering, CEO, Christian Brothers University, SVKM's NMIMS, Nasdaq, Enos, Kellogg School, Surgeon, Motion, Smith & Nephew, Corporate development, University of Illinois Urbana-Champaign, Marketing, GLOBE, Business development, Intuitive Surgical, Northwestern University, Risk management, Management, Science, Titan

TORONTO, ON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that Eric Heinz has been appointed as the companys Vice President, Market and Corporate Development.

Key Points: 
  • TORONTO, ON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that Eric Heinz has been appointed as the companys Vice President, Market and Corporate Development.
  • Mr. Heinz will engage and collaborate with stakeholders in refining the companys value proposition, branding, product positioning and core messaging.
  • Eric brings a proven track record of leading efforts to grow businesses and augment markets in the dynamic surgical robotics industry.
  • Mr. Heinz has more than 20 years of medical device experience across business strategy, corporate development, product development and marketing for companies ranging in size from small-cap to multi-nationals.